tiprankstipranks
Trending News
More News >

Argenica Therapeutics to Host Investor Webinar on Phase 2 Stroke Trial Progress

Story Highlights
Argenica Therapeutics to Host Investor Webinar on Phase 2 Stroke Trial Progress

Confident Investing Starts Here:

Argenica Therapeutics Ltd ( (AU:AGN) ) has issued an announcement.

Argenica Therapeutics Ltd announced an upcoming investor webinar where CEO Dr. Liz Dallimore will discuss the company’s progress, particularly focusing on the Phase 2 Clinical Trial for Acute Ischaemic Stroke. This event signifies an important step in Argenica’s efforts to advance their neuroprotective peptide, ARG-007, potentially impacting the treatment landscape for stroke and other neurological conditions.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Ltd is a company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other brain injuries, as well as neurodegenerative diseases. Their lead product, ARG-007, has shown promise in improving outcomes in pre-clinical models of stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy. The company has completed a Phase 1 clinical trial to assess the safety of ARG-007 and is currently conducting a Phase 2 trial in ischaemic stroke patients.

Average Trading Volume: 108,624

Technical Sentiment Signal: Buy

Learn more about AGN stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1